Remdesivir (Synonyms: GS-5734)

Name: Remdesivir
Brand: MedChemExpress
SKU: HY-104077
Rating: 5.0 (214 reviews)

Cat. No.: HY-104077 Purity: 99.95%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Remdesivir (GS-5734) is a nucleoside analogue with effective antiviral activity. Remdesivir can inhibit the synthesis of viral DNA or RNA. Remdesivir can be used for the research of infection, such as SARS-CoV and MHV infection.

For research use only. We do not sell to patients.

CAS No. : 1809249-37-3

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
1 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
250 mg	In-stock	Estimated Time of Arrival: December 31
500 mg	Get quote
1 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 214 publication(s) in Google Scholar

Other Forms of Remdesivir:

GS-441524 In-stock
Remdesivir-d₅ In-stock
Remdesivir (Standard) In-stock
Remdesivir-d₄ Get quote
Remdesivir impurity 9-d₄ Get quote
GS-443902 Get quote
Remdesivir-¹³C₆ Get quote
Remdesivir maleate Get quote

214 Publications Citing Use of MCE Remdesivir

Bio/Physico-chemical Assay

Cell Proliferation/Viability Assay

: Remdesivir purchased from MedChemExpress. Usage Cited in: Nat Cell Biol. 2023 Aug;25(8):1223-1234. [Abstract]; Virus titre expressed in ‘Luminescence relative light units (RLU)’ and genome copy analysis of d5 infected STs ± antiviral drug treatment (Rem = Remdesivir (1 μM; 3 h); NHC = Molnupiravir).

: Remdesivir purchased from MedChemExpress. Usage Cited in: Science. 2021 Nov 26;374(6571):1099-1106. [Abstract]; Time course measurements of cell viability of Huh-7.5 cells electroporated with WT or Nsp1 K164A/H165A double mutant (Nsp1mut) Gluc replicon RNA. Cells were seeded with 100 nM Remdesivir or vehicle and were washed in phosphate-buffered saline 24 hours before each respective time-point collection. Mock-electroporated cells were used as controls for post-electroporation cell viability. The dashed line indicates the limit of detection. N = 4. Error bars indicate SD.

: Remdesivir purchased from MedChemExpress. Usage Cited in: Nature. 2020 Jun;582(7813):561-565. [Abstract]; Remdesivir treatment showing the use of synSARS-CoV-2-GFP. Vero E6 cells were infected with synSARS-CoV-2-GFP (MOI = 0.01) and treated with 0.2 μM, 2 μM or without Remdesivir. DMSO was used as treatment in cells that were not incubated with Remdesivir. Mock, uninfected cells. At 48 h after infection, cells were analysed by fluorescence microscopy to detect GFP expression (left) and cell-culture supernatants were collected and titrated by TCID50 assay (right).

: Remdesivir purchased from MedChemExpress. Usage Cited in: Cell Res. 2020 Mar;30(3):269-271. [Abstract]; Remdesivir (0.21-5.56 μM) inhibits virus infection efficiently in a human cell line (human liver cancer Huh-7 cells), which is sensitive to 2019-nCoV.2.

: Remdesivir purchased from MedChemExpress. Usage Cited in: Sci Bull. 2021 May 15;66(9):925-936. [Abstract]; Immunofluorescence of intracellular viral N protein. Intracellular expression of N protein was assessed by staining of infected Vero E6 cells with the polyclonal anti-N antibody (1:1000 dilution, green). Nuclei were stained with DAPI. CPE was shown in bright field. The results showed that Remdesivir (6.25 µmol/L) significantly inhibited N protein expression.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All DNA/RNA Synthesis Isoform Specific Products:

View All Isoforms

RNASE L DNA Polymerases RNA Polymerases Helicases DNA Ligase

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

EC₅₀: 30 nM (murine hepatitis virus, delayed brain tumor cell), 74 nM (SARS-CoV, HAE cell), 74 nM (MERS-CoV, HAE cell)^[1]
EC₅₀: 3.3 μM (SARS-CoV-2), 4.7 μM (SARS-CoV-2 alpha), 32 μM (SARS-CoV-2 beta), 3.7 μM (SARS-CoV-2 gamma) and 9.2 μM (SARS-CoV-2 delta)^[3]

Cellular Effect

Cell Line	Type	Value	Description	References
16HBE14o-	CC₅₀	41 μM Compound: Remdesivir	Cytotoxicity against human 16HBE14o- after 72 hrs by MTT assay Cytotoxicity against human 16HBE14o- after 72 hrs by MTT assay	[PMID: 34408808]
A549	CC₅₀	43 μM Compound: Remdesivir	Cytotoxicity against human A549 cells overexpressing ACE2 and TMPRSS2 incubated for 48 hrs by MTS assay Cytotoxicity against human A549 cells overexpressing ACE2 and TMPRSS2 incubated for 48 hrs by MTS assay	[PMID: 36097498]
CCRF-CEM	CC₅₀	11.2 μM Compound: Remdesivir	Cytotoxicity against human CEM cells assessed as reduction in cell viability Cytotoxicity against human CEM cells assessed as reduction in cell viability	[PMID: 38432056]
Caco-2	CC₅₀	2584.38 μM Compound: REMDESIVIR	Toxicity against Caco-2 cells determined at 48 hours by intracellular ATP concentration using the CellTiter-Glo Luminescent Cell Viability Assay Toxicity against Caco-2 cells determined at 48 hours by intracellular ATP concentration using the CellTiter-Glo Luminescent Cell Viability Assay	10.21203/rs.3.rs-23951/v1
Caco-2	CC₅₀	80 μM Compound: Remdesivir	Cytotoxicity against human Caco2 cells infected with SARS-COV-2 assessed as reduction in cell viability by celltiter-glo luminescent cell viability assay Cytotoxicity against human Caco2 cells infected with SARS-COV-2 assessed as reduction in cell viability by celltiter-glo luminescent cell viability assay	[PMID: 34273661]
Caco-2	CC₅₀	> 100 μM Compound: Remdesivir	Cytotoxicity against human Caco-2 cells assessed as reduction in cell viability Cytotoxicity against human Caco-2 cells assessed as reduction in cell viability	[PMID: 38432056]
Caco-2	IC₅₀	0.76 μM Compound: REMDESIVIR	Determination of IC50 values for inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells after 48 hours by high content imaging Determination of IC50 values for inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells after 48 hours by high content imaging	10.21203/rs.3.rs-23951/v1
Calu-3	CC₅₀	97 μM Compound: Remdesivir	Cytotoxicity against human Calu-3 cells infected with SARS-COV-2 by celltiter-glo luminescent cell viability assay Cytotoxicity against human Calu-3 cells infected with SARS-COV-2 by celltiter-glo luminescent cell viability assay	[PMID: 34273661]
Calu-3	CC₅₀	> 0.1 μM Compound: 1	Cytotoxicity against human Calu-3 cells assessed as reduction in cell viability Cytotoxicity against human Calu-3 cells assessed as reduction in cell viability	[PMID: 36651644]
Calu-3	CC₅₀	> 10 μM Compound: Remdesivir	Cytotoxicity against human Calu-3 cells infected with SARS CoV-2 USA-WA1/2020 clinical isolate assessed as reduction in cell viability incubated for 48 hrs by imaging analysis Cytotoxicity against human Calu-3 cells infected with SARS CoV-2 USA-WA1/2020 clinical isolate assessed as reduction in cell viability incubated for 48 hrs by imaging analysis	[PMID: 37482021]
Calu-3	CC₅₀	> 100 μM Compound: Remdesivir	Cytotoxicity against human Calu-3 cells assessed as reduction in cell viability incubated for 48 hrs by PrestoBlue reagent based assay Cytotoxicity against human Calu-3 cells assessed as reduction in cell viability incubated for 48 hrs by PrestoBlue reagent based assay	[PMID: 36399766]
Calu-3	CC₅₀	> 100 μM Compound: Remdesivir	Cytotoxicity against human Calu-3 cells measured after 2 days by MTT assay Cytotoxicity against human Calu-3 cells measured after 2 days by MTT assay	[PMID: 37633203]
Calu-3	CC₅₀	> 100 μM Compound: Remdesivir	Cytotoxicity against human Calu-3 cells assessed as reduction in cell viability Cytotoxicity against human Calu-3 cells assessed as reduction in cell viability	[PMID: 38432056]
Calu-3	CC₅₀	> 5 μM Compound: Remdesivir	Cytotoxicity against human Calu-3 cells assessed as reduction in cell viability Cytotoxicity against human Calu-3 cells assessed as reduction in cell viability	[PMID: 35290044]
Calu-3	CC₅₀	> 50 μM Compound: RDV	Cytotoxicity against human Calu-3 cells assessed as reduction in cell viability after 48 hrs by Cell-Tox green based fluorescence assay Cytotoxicity against human Calu-3 cells assessed as reduction in cell viability after 48 hrs by Cell-Tox green based fluorescence assay	[PMID: 34583312]
HCT-8	CC₅₀	53.18 μM Compound: Remdesivir	Cytotoxicity against human HCT-8 cells assessed as redcution in cell viability incubated for 96 hrs by PrestoBlue reagent based assay Cytotoxicity against human HCT-8 cells assessed as redcution in cell viability incubated for 96 hrs by PrestoBlue reagent based assay	[PMID: 36399766]
HEK-293T	CC₅₀	> 100 μM Compound: Remdesivir	Cytotoxicity against human HEK293T cells assessed as reduction in cell viability incubated for 24 hrs by CCK8 assay Cytotoxicity against human HEK293T cells assessed as reduction in cell viability incubated for 24 hrs by CCK8 assay	[PMID: 34147744]
HEL 299	CC₅₀	> 10 μM Compound: Remdesivir	Cytotoxicity against human HEL 299 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay Cytotoxicity against human HEL 299 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay	[PMID: 37252100]
HEp-2	CC₅₀	6.1 μM Compound: 1; GS-5734	Cytotoxicity against human HEp-2 cells assessed as reduction in cell viability incubated for 4 to 5 days by CellTiter Glo viability assay Cytotoxicity against human HEp-2 cells assessed as reduction in cell viability incubated for 4 to 5 days by CellTiter Glo viability assay	[PMID: 33835812]
HEp-2	CC₅₀	6.1 μM Compound: 4b	Cytotoxicity against human Hep2 cells assessed as reduction in cell viability after 4 to 5 days by Cell-Titer Glo assay Cytotoxicity against human Hep2 cells assessed as reduction in cell viability after 4 to 5 days by Cell-Titer Glo assay	[PMID: 28124907]
HEp-2	CC₅₀	9.2 μM Compound: 18j	Cytotoxicity against human HEp-2 cells assessed as reduction in cell viability incubated for 4 to 5 days by CellTiter Glo viability assay Cytotoxicity against human HEp-2 cells assessed as reduction in cell viability incubated for 4 to 5 days by CellTiter Glo viability assay	[PMID: 33835812]
HEp-2	CC₅₀	9.2 μM Compound: 4a, mixture of Sp/Rp isomer	Cytotoxicity against human Hep2 cells assessed as reduction in cell viability after 4 to 5 days by Cell-Titer Glo assay Cytotoxicity against human Hep2 cells assessed as reduction in cell viability after 4 to 5 days by Cell-Titer Glo assay	[PMID: 28124907]
HEp-2	EC₅₀	0.015 μM Compound: 1; GS-5734	Antiviral activity against RSV A2 infected in HEp-2 cells assessed as reduction in virus-induced cytopathic effect after 4 days by CellTiter Glo viability assay Antiviral activity against RSV A2 infected in HEp-2 cells assessed as reduction in virus-induced cytopathic effect after 4 days by CellTiter Glo viability assay	[PMID: 33835812]
HEp-2	EC₅₀	0.027 μM Compound: 18j	Antiviral activity against RSV A2 infected in HEp-2 cells assessed as reduction in virus-induced cytopathic effect after 4 days by CellTiter Glo viability assay Antiviral activity against RSV A2 infected in HEp-2 cells assessed as reduction in virus-induced cytopathic effect after 4 days by CellTiter Glo viability assay	[PMID: 33835812]
HEp-2	IC₅₀	0.11 μM Compound: 1; GS-5734	Drug metabolism in human HEp-2 cells assessed as 1-NTP metabolite concentration at EC50 over 48 hrs by LC-MS/MS analysis Drug metabolism in human HEp-2 cells assessed as 1-NTP metabolite concentration at EC50 over 48 hrs by LC-MS/MS analysis	[PMID: 33835812]
HeLa	CC₅₀	> 20 μM Compound: 3; GS-5734	Cytotoxicity against human HeLa after 4 to 5 days by Cell-Titer Glo viability assay Cytotoxicity against human HeLa after 4 to 5 days by Cell-Titer Glo viability assay	[PMID: 28792763]
HeLa	EC₅₀	0.1 μM Compound: 4b	Antiviral activity against Ebolavirus Kikwit infected in human HeLa cells assessed as reduction in viral glycoprotein levels preincubated with cells for 2 hrs followed by viral infection measured after 48 hrs by immunostaining based assay Antiviral activity against Ebolavirus Kikwit infected in human HeLa cells assessed as reduction in viral glycoprotein levels preincubated with cells for 2 hrs followed by viral infection measured after 48 hrs by immunostaining based assay	[PMID: 28124907]
HeLa	EC₅₀	0.14 μM Compound: 3; GS-5734	Antiviral activity against Ebolavirus infected in human HeLa cells after 48 hrs by immuno-staining assay Antiviral activity against Ebolavirus infected in human HeLa cells after 48 hrs by immuno-staining assay	[PMID: 28792763]
HeLa	EC₅₀	0.17 μM Compound: 4a, mixture of Sp/Rp isomer	Antiviral activity against Ebolavirus Kikwit infected in human HeLa cells assessed as reduction in viral glycoprotein levels preincubated with cells for 2 hrs followed by viral infection measured after 48 hrs by immunostaining based assay Antiviral activity against Ebolavirus Kikwit infected in human HeLa cells assessed as reduction in viral glycoprotein levels preincubated with cells for 2 hrs followed by viral infection measured after 48 hrs by immunostaining based assay	[PMID: 28124907]
HepG2	CC₅₀	11.1 μM Compound: 1; RDV	Cytotoxicity against human HepG2 cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay Cytotoxicity against human HepG2 cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay	[PMID: 37596939]
HepG2	CC₅₀	52.62 μM Compound: Remdesivir	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by PrestoBlue reagent based assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by PrestoBlue reagent based assay	[PMID: 36399766]
Hepatocyte	CC₅₀	2.5 μM Compound: 1; RDV	Cytotoxicity against human primary hepatocytes assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay Cytotoxicity against human primary hepatocytes assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay	[PMID: 37596939]
Huh-7	CC₅₀	1.4 μM Compound: Remdesivir	Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability	[PMID: 38432056]
Huh-7	CC₅₀	10.37 μM Compound: Remdesivir	Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability incubated for 24 hrs by Celltiter-glo luminescent cell viability assay Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability incubated for 24 hrs by Celltiter-glo luminescent cell viability assay	[PMID: 34242027]
Huh-7	CC₅₀	17 μM Compound: 4a, mixture of Sp/Rp isomer	Cytotoxicity against human HuH7 cells assessed as reduction in cell viability after 3 days by calcein-AM dye based fluorescence assay Cytotoxicity against human HuH7 cells assessed as reduction in cell viability after 3 days by calcein-AM dye based fluorescence assay	[PMID: 28124907]
Huh-7	CC₅₀	36 μM Compound: 4b	Cytotoxicity against human HuH7 cells assessed as reduction in cell viability after 3 days by calcein-AM dye based fluorescence assay Cytotoxicity against human HuH7 cells assessed as reduction in cell viability after 3 days by calcein-AM dye based fluorescence assay	[PMID: 28124907]
Huh-7	CC₅₀	77 μM Compound: Remdesivir	Cytotoxicity against human Huh-7 cells infected with SARS-COV-2 assessed as reduction in cell viability by celltiter-glo luminescent cell viability assay Cytotoxicity against human Huh-7 cells infected with SARS-COV-2 assessed as reduction in cell viability by celltiter-glo luminescent cell viability assay	[PMID: 34273661]
Huh-7	CC₅₀	90 μM Compound: Remdesivir	Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay	[PMID: 39028935]
Huh-7	CC₅₀	> 10 μM Compound: GS-5734; 8b	Cytotoxicity against human Huh-7 cells by celltiter-glo Assay Cytotoxicity against human Huh-7 cells by celltiter-glo Assay	[PMID: 32563812]
Huh-7	CC₅₀	> 10 μM Compound: RDV; GS-5734	Cytotoxicity against human Huh-7 cells by CellTiter-Glo assay Cytotoxicity against human Huh-7 cells by CellTiter-Glo assay	[PMID: 32845145]
Huh-7	CC₅₀	> 10 μM Compound: RDV; GS-5734	Cytotoxicity against human Huh7 cells incubated for 6 days by cellTiter-Glo assay Cytotoxicity against human Huh7 cells incubated for 6 days by cellTiter-Glo assay	[PMID: 32845145]
Huh-7	CC₅₀	> 10 μM Compound: Remdesivir	Cytotoxicity against human Huh-7 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay Cytotoxicity against human Huh-7 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay	[PMID: 37252100]
Huh-7	CC₅₀	> 20 μM Compound: 3; GS-5734	Cytotoxicity against human HuH7 after 4 to 5 days by Cell-Titer Glo viability assay Cytotoxicity against human HuH7 after 4 to 5 days by Cell-Titer Glo viability assay	[PMID: 28792763]
Huh-7	CC₅₀	> 50 μM Compound: RDV	Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability measured after 24 hrs by CellTiter-Glo analysis Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability measured after 24 hrs by CellTiter-Glo analysis	[PMID: 34583312]
MRC5	CC₅₀	> 100 μM Compound: Remdesivir	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 24 hrs by Celltiter-glo luminescent cell viability assay Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 24 hrs by Celltiter-glo luminescent cell viability assay	[PMID: 34242027]
MRC5	CC₅₀	> 100 μM Compound: Remdesivir	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 48 hrs by PrestoBlue reagent based assay Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 48 hrs by PrestoBlue reagent based assay	[PMID: 36399766]
MT4	CC₅₀	1.7 μM Compound: 1; RDV	Cytotoxicity against human MT4 cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay Cytotoxicity against human MT4 cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay	[PMID: 37596939]
MT4	CC₅₀	1.7 μM Compound: 4b	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 4 to 5 days by Cell-Titer Glo assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 4 to 5 days by Cell-Titer Glo assay	[PMID: 28124907]
MT4	CC₅₀	2 μM Compound: 4a, mixture of Sp/Rp isomer	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 4 to 5 days by Cell-Titer Glo assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 4 to 5 days by Cell-Titer Glo assay	[PMID: 28124907]
Macrophage	CC₅₀	> 20 μM Compound: 3; GS-5734	Cytotoxicity against human primary macrophages after 4 to 5 days by Cell-Titer Glo viability assay Cytotoxicity against human primary macrophages after 4 to 5 days by Cell-Titer Glo viability assay	[PMID: 28792763]
PBMC	CC₅₀	14.8 μM Compound: 1; RDV	Cytotoxicity against stimulated human PBMC cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay Cytotoxicity against stimulated human PBMC cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay	[PMID: 37596939]
PBMC	CC₅₀	2 μM Compound: Remdesivir	Cytotoxicity against human PBMC cells assessed as inhibition of cell proliferation incubated for 2 to 4 days by CellTiter 96 non-radioactive cell proliferation assay Cytotoxicity against human PBMC cells assessed as inhibition of cell proliferation incubated for 2 to 4 days by CellTiter 96 non-radioactive cell proliferation assay	[PMID: 38242544]
PBMC	CC₅₀	4.9 μM Compound: Remdesivir	Cytotoxicity against human PBMC cells assessed as reduction in cell viability Cytotoxicity against human PBMC cells assessed as reduction in cell viability	[PMID: 38432056]
PBMC	CC₅₀	> 20 μM Compound: 1; RDV	Cytotoxicity against quiescent human PBMC cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay Cytotoxicity against quiescent human PBMC cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay	[PMID: 37596939]
PC-3	CC₅₀	1.4 μM Compound: 1; RDV	Cytotoxicity against human PC-3 cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay Cytotoxicity against human PC-3 cells assessed as reduction in cell growth measured after 5 days by CellTiter-Glo assay	[PMID: 37596939]
Vero	CC₅₀	70.6 μM Compound: Remdesivir	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell growth by Coulter counter analysis Cytotoxicity against African green monkey Vero cells assessed as reduction in cell growth by Coulter counter analysis	[PMID: 36332548]
Vero	CC₅₀	> 10 μM Compound: Remdesivir	Cytotoxicity against African green monkey Vero cells incubated for 5 days by neutral red uptake assay Cytotoxicity against African green monkey Vero cells incubated for 5 days by neutral red uptake assay	[PMID: 37482021]
Vero	CC₅₀	> 100 μM Compound: RDV	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 36764470]
Vero	CC₅₀	> 100 μM Compound: Remdesivir	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 48 hrs by PrestoBlue reagent based assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 48 hrs by PrestoBlue reagent based assay	[PMID: 36399766]
Vero	CC₅₀	> 100 μM Compound: Remdesivir	Cytotoxicity against African green monkey Vero cells assessed as inhibition of cell proliferation incubated for 2 to 4 days by CellTiter 96 non-radioactive cell proliferation assay Cytotoxicity against African green monkey Vero cells assessed as inhibition of cell proliferation incubated for 2 to 4 days by CellTiter 96 non-radioactive cell proliferation assay	[PMID: 38242544]
Vero	CC₅₀	> 100 μM Compound: Remdesivir	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability	[PMID: 38432056]
Vero	CC₅₀	> 25 μM Compound: Remdesivir	Cell viability measured by CellTiter-Glo assay in Vero cells at MOI 0.05 after 72hr Cell viability measured by CellTiter-Glo assay in Vero cells at MOI 0.05 after 72hr	10.1101/2020.03.20.999730
Vero	CC₅₀	> 25 μM Compound: Remdesivir	Cytotoxicity against African green monkey Vero cells infected with SARS-CoV-2 betaCoV/KOR/KCDC03/2020 assessed as reduction in cell viability measured after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay Cytotoxicity against African green monkey Vero cells infected with SARS-CoV-2 betaCoV/KOR/KCDC03/2020 assessed as reduction in cell viability measured after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay	[PMID: 33160024]
Vero	CC₅₀	> 25 μM Compound: Remdesivir	Cytotoxicity against african green monkey Vero cells Cytotoxicity against african green monkey Vero cells	[PMID: 36870624]
Vero	CC₅₀	> 40 μM Compound: Remdesivir	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell growth by coulter counter analysis Cytotoxicity against African green monkey Vero cells assessed as reduction in cell growth by coulter counter analysis	[PMID: 33479570]
Vero	CC₅₀	> 40 μM Compound: Remdesivir	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability by coulter counter method Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability by coulter counter method	[PMID: 34571172]
Vero	CC₅₀	> 40 μM Compound: Remdesivir	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell growth by coulter counter method Cytotoxicity against African green monkey Vero cells assessed as reduction in cell growth by coulter counter method	[PMID: 38232463]
Vero	EC₅₀	0.61 μM Compound: Remdesivir	Antiviral activity against Severe acute respiratory syndrome coronavirus 2 UC-1075 infected in African green monkey Vero cells assessed as reduction in plaque formation measured after 5 days by microscopic analysis Antiviral activity against Severe acute respiratory syndrome coronavirus 2 UC-1075 infected in African green monkey Vero cells assessed as reduction in plaque formation measured after 5 days by microscopic analysis	[PMID: 34571172]
Vero	EC₅₀	2.3 μM Compound: Remdesivir	Antiviral activity against SARS-CoV-2 USA-WA1/2020 infected in african green monkey Vero cells assessed as reduction in viral replication by qRT-PCR analysis Antiviral activity against SARS-CoV-2 USA-WA1/2020 infected in african green monkey Vero cells assessed as reduction in viral replication by qRT-PCR analysis	[PMID: 38242544]
Vero	IC₅₀	11.41 μM Compound: Remdesivir	Antiviral activity against SARS-CoV-2 (viral titer) measured by plaque assay in Vero cells at MOI 0.0125 after 24 hr Antiviral activity against SARS-CoV-2 (viral titer) measured by plaque assay in Vero cells at MOI 0.0125 after 24 hr	10.1101/2020.03.20.999730
Vero C1008	CC₅₀	100 μM Compound: RDV; GS-5734	Cytotoxicity against African green monkey Vero E6 cells by the CCK8 assay Cytotoxicity against African green monkey Vero E6 cells by the CCK8 assay	[PMID: 32845145]
Vero C1008	CC₅₀	166 μM Compound: Remdesivir	Cytotoxicity against African green monkey Vero E6 cells infected with SARS-COV-2 by celltiter-glo luminescent cell viability assay Cytotoxicity against African green monkey Vero E6 cells infected with SARS-COV-2 by celltiter-glo luminescent cell viability assay	[PMID: 34273661]
Vero C1008	CC₅₀	168 nM Compound: Remdesivir	Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability incubated for 72 hrs by crystal violet staining based analysis Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability incubated for 72 hrs by crystal violet staining based analysis	[PMID: 39004019]
Vero C1008	CC₅₀	373 μM Compound: RMV	Cytotoxicity against African green monkey Vero E6 cells assessed as reduction of cell viability measured after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero E6 cells assessed as reduction of cell viability measured after 72 hrs by MTT assay	[PMID: 34534839]
Vero C1008	CC₅₀	608.3 μM Compound: Cpd III	Cytotoxicity against African green monkey Vero E6 cells measured after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero E6 cells measured after 72 hrs by MTT assay	[PMID: 37252103]
Vero C1008	CC₅₀	72 μM Compound: Remdesivir	Cytotoxicity against African green monkey Vero E6 cells after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero E6 cells after 72 hrs by MTT assay	[PMID: 34408808]
Vero C1008	CC₅₀	> 10 μM Compound: GS-5734	Cytotoxicity against african green monkey Vero E6 cells by MTS assay Cytotoxicity against african green monkey Vero E6 cells by MTS assay	[PMID: 36455356]
Vero C1008	CC₅₀	> 100 μM Compound: GS-5734; 8b	Cytotoxicity against African green monkey Vero E6 cells Cytotoxicity against African green monkey Vero E6 cells	[PMID: 32563812]
Vero C1008	CC₅₀	> 100 μM Compound: Remdesivir	Cytotoxicity against african green monkey Vero E6 cells assessed as reduction in cell viability after 26 hrs by MTS assay Cytotoxicity against african green monkey Vero E6 cells assessed as reduction in cell viability after 26 hrs by MTS assay	[PMID: 36475694]
Vero C1008	CC₅₀	> 100 μM Compound: Remdesivir	Cytotoxicity against african green monkey Vero E6 cells assessed as inhibition of cell growth by CCK-8 assay Cytotoxicity against african green monkey Vero E6 cells assessed as inhibition of cell growth by CCK-8 assay	[PMID: 36965227]
Vero C1008	CC₅₀	> 100 μM Compound: Remdesivir	Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay	[PMID: 39028935]
Vero C1008	CC₅₀	> 200 μM Compound: Remdesivir	Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay	[PMID: 34749200]
Vero C1008	EC₅₀	0.069 μM Compound: 52	Antiviral activity against SARS-CoV infected in Vero E6 cells assessed as reduction in viral replication measured after 48 hrs by qRT-PCR assay Antiviral activity against SARS-CoV infected in Vero E6 cells assessed as reduction in viral replication measured after 48 hrs by qRT-PCR assay	[PMID: 33486200]
Vero C1008	EC₅₀	0.074 μM Compound: 52	Antiviral activity against MERS-CoV infected in Vero E6 cells assessed as reduction in viral replication measured after 48 hrs by qRT-PCR assay Antiviral activity against MERS-CoV infected in Vero E6 cells assessed as reduction in viral replication measured after 48 hrs by qRT-PCR assay	[PMID: 33486200]
Vero C1008	EC₅₀	0.62 μM Compound: Remdesivir	Determination of antiviral efficacy in high-content imaging assay in Vero E6 cells infected with SARS-CoV-2 (USA-WA1/2020 isolate) at MOI 0.75 after 24 hrs Determination of antiviral efficacy in high-content imaging assay in Vero E6 cells infected with SARS-CoV-2 (USA-WA1/2020 isolate) at MOI 0.75 after 24 hrs	10.1101/2020.04.16.044016
Vero C1008	EC₅₀	0.77 μM Compound: 52	Antiviral activity against SARS-CoV-2 infected in Vero E6 cells assessed as reduction in viral replication measured after 48 hrs by qRT-PCR assay Antiviral activity against SARS-CoV-2 infected in Vero E6 cells assessed as reduction in viral replication measured after 48 hrs by qRT-PCR assay	[PMID: 33486200]
Vero C1008	EC₅₀	1.65 μM Compound: Remdesivir	Antiviral efficacy against SARS-CoV-2 (strain BavPat1) in Vero E6 cells assessed by inhibition of viral RNA replication measured by RT-PCR after 2 days Antiviral efficacy against SARS-CoV-2 (strain BavPat1) in Vero E6 cells assessed by inhibition of viral RNA replication measured by RT-PCR after 2 days	10.1101/2020.04.03.023846
Vero C1008	EC₅₀	3.01 μM Compound: Remdesivir	Antiviral activity against SARS coronavirus 2 infected in Vero E6 cells assessed as plague reduction measured after 1 hr Antiviral activity against SARS coronavirus 2 infected in Vero E6 cells assessed as plague reduction measured after 1 hr	[PMID: 33639344]
Vero C1008	EC₅₀	770 nM Compound: GS-5734	Antiviral activity against SARS-COV-2 infected in African green monkey Vero E6 cells Antiviral activity against SARS-COV-2 infected in African green monkey Vero E6 cells	[PMID: 37229831]

In Vitro

Remdesivir inhibits MHV replication with an IC₅₀ of 1.1 μM in infected delayed brain tumor (DBT) cells with MHV^[1].
Remdesivir (2 μM, 2 h preinfection and 2 h postinfection) shows maximal inhibition in infected cells with MHV^[1].
Remdesivir (1-10 μM, 24-72 h) decreases SARS-CoV and MERS-CoV viral titer in HAE cells^[1].
Remdesivir inhibits 2019-nCoV with an EC₅₀ of 0.77 μM and CC₅₀ >100 μM^[2].
Remdesivir shows antiviral activity with EC₅₀ values of 3.3 μM, 4.7 μM, 32 μM, 3.7 μM and 9.2 μM for SARS-CoV-2 and its variants alpha, beta, gamma and delta, respectively^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Remdesivir (0.01-100 μM) reduces lung viral titers in mice models of WT and F480L + V557L SARS-CoV^[1].
Remdesivir (10 mg/kg, i.v.) shows 100% protection against Ebola virus infection in nonhuman primate (NHP) models^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Molecular Weight

602.58

Formula

C₂₇H₃₅N₆O₈P

CAS No.

1809249-37-3

Appearance

Solid

Color

Off-white to yellow

SMILES

C[C@H](N[P@@](OC1=CC=CC=C1)(OC[C@H]2O[C@@](C#N)(C3=CC=C4C(N)=NC=NN43)[C@H](O)[C@@H]2O)=O)C(OCC(CC)CC)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (165.95 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.6595 mL	8.2977 mL	16.5953 mL
5 mM	0.3319 mL	1.6595 mL	3.3191 mL
10 mM	0.1660 mL	0.8298 mL	1.6595 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.15 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 2

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.17 mg/mL (3.60 mM); Clear solution

This protocol yields a clear solution of ≥ 2.17 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (21.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.17 mg/mL (3.60 mM); Clear solution

This protocol yields a clear solution of ≥ 2.17 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (21.7 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.95%

Select Batch:

Data Sheet (276 KB) SDS (558 KB)

COA (250 KB) LCMS (94 KB)

Handling Instructions (2659 KB)

References

[1]. Agostini ML, et al. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. MBio. 2018 Mar 6;9(2). pii: e00221-18. [Content Brief]

[2]. Wang M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. [Content Brief]

[3]. Hu H, et al. Optimization of the Prodrug Moiety of Remdesivir to Improve Lung Exposure/Selectivity and Enhance Anti-SARS-CoV-2 Activity. J Med Chem. 2022 Sep 22;65(18):12044-12054. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.6595 mL	8.2977 mL	16.5953 mL	41.4883 mL
	5 mM	0.3319 mL	1.6595 mL	3.3191 mL	8.2977 mL
	10 mM	0.1660 mL	0.8298 mL	1.6595 mL	4.1488 mL
	15 mM	0.1106 mL	0.5532 mL	1.1064 mL	2.7659 mL
	20 mM	0.0830 mL	0.4149 mL	0.8298 mL	2.0744 mL
	25 mM	0.0664 mL	0.3319 mL	0.6638 mL	1.6595 mL
	30 mM	0.0553 mL	0.2766 mL	0.5532 mL	1.3829 mL
	40 mM	0.0415 mL	0.2074 mL	0.4149 mL	1.0372 mL
	50 mM	0.0332 mL	0.1660 mL	0.3319 mL	0.8298 mL
	60 mM	0.0277 mL	0.1383 mL	0.2766 mL	0.6915 mL
	80 mM	0.0207 mL	0.1037 mL	0.2074 mL	0.5186 mL
	100 mM	0.0166 mL	0.0830 mL	0.1660 mL	0.4149 mL

Remdesivir Related Classifications

Infection

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Remdesivir1809249-37-3GS-5734GS5734GS 5734DNA/RNA SynthesisSARS-CoVSARS coronavirusMHVMERS-CoVInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Remdesivir (Synonyms: GS-5734)

Customer Review

Other Forms of Remdesivir:

Remdesivir Related Antibodies

214 Publications Citing Use of MCE Remdesivir

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All DNA/RNA Synthesis Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Remdesivir Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Remdesivir Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report